Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17388254 | 1.00 | ELANE (0.33) | ELANECNR2NPC1CNR1CYP1A2 | |
| SCHEMBL14562352 | 1.00 | ELANE (0.33) | ELANECNR2NPC1CNR1CYP1A2 | |
| SCHEMBL17414527 | 1.00 | ELANE (0.33) | ELANECNR2NPC1CNR1CYP1A2 | |
| SCHEMBL31320358 | 1.00 | ELANE (0.33) | ELANECNR2NPC1CNR1CYP1A2 | |
| SCHEMBL26201200 | 0.86 | CNR2 (0.33) | ELANECNR2NPC1CNR1CYP1A2 | |
| SCHEMBL26201119 | 0.85 | GSTP1 (0.36) | CNR2 | |
| SCHEMBL27026223 | 0.75 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL26201185 | 0.75 | ELANE (0.32) | ELANENPC1 | |
| SCHEMBL20192086 | 0.75 | NPC1 (0.33) | ELANENPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24281977 | 0.74 | ELANE (0.34) | ELANECNR2NPC1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2023-08-31 | — | — | US | disclosed |
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2023-08-31 | — | — | US | disclosed |
| WO-2022061461-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2022-03-31 | — | — | WO | disclosed |
| US-9428431-B2 | Compositions comprising CB receptor agonists, uses thereof and methods for their preparation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-9428431-B2 | Compositions comprising CB receptor agonists, uses thereof and methods for their preparation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20110269842-A1 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2011-11-03 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269842-A1 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | CNR1, CNR2, ADRA2C | ELANE 3436/4885CNR2 2/4885NPC1 734/4885 |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | ELANE 1995/4885CNR2 1/4885NPC1 2119/4885 |
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | CYP3A43, PRMT8, MGMT | ELANE 1084/4885CNR2 2295/4885NPC1 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.